Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Prophylactic Efficacy of Quercetin 3-β-O-d-Glucoside against Ebola Virus Infection.

Qiu X, Kroeker A, He S, Kozak R, Audet J, Mbikay M, Chrétien M.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5182-8. doi: 10.1128/AAC.00307-16. Print 2016 Sep.

2.

Antiviral effect of ranpirnase against Ebola virus.

Hodge T, Draper K, Brasel T, Freiberg A, Squiquera L, Sidransky D, Sulley J, Taxman DJ.

Antiviral Res. 2016 Aug;132:210-8. doi: 10.1016/j.antiviral.2016.06.009. Epub 2016 Jun 25.

PMID:
27350309
3.

Teicoplanin inhibits Ebola pseudovirus infection in cell culture.

Wang Y, Cui R, Li G, Gao Q, Yuan S, Altmeyer R, Zou G.

Antiviral Res. 2016 Jan;125:1-7. doi: 10.1016/j.antiviral.2015.11.003. Epub 2015 Nov 14.

PMID:
26585243
4.

Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection.

Swenson DL, Warfield KL, Warren TK, Lovejoy C, Hassinger JN, Ruthel G, Blouch RE, Moulton HM, Weller DD, Iversen PL, Bavari S.

Antimicrob Agents Chemother. 2009 May;53(5):2089-99. doi: 10.1128/AAC.00936-08. Epub 2009 Feb 17.

5.

Antiviral activity of quercetin-3-β-O-D-glucoside against Zika virus infection.

Wong G, He S, Siragam V, Bi Y, Mbikay M, Chretien M, Qiu X.

Virol Sin. 2017 Dec;32(6):545-547. doi: 10.1007/s12250-017-4057-9.

6.

Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus.

Barrientos LG, O'Keefe BR, Bray M, Sanchez A, Gronenborn AM, Boyd MR.

Antiviral Res. 2003 Mar;58(1):47-56.

PMID:
12719006
7.

Interferon-γ Inhibits Ebola Virus Infection.

Rhein BA, Powers LS, Rogers K, Anantpadma M, Singh BK, Sakurai Y, Bair T, Miller-Hunt C, Sinn P, Davey RA, Monick MM, Maury W.

PLoS Pathog. 2015 Nov 12;11(11):e1005263. doi: 10.1371/journal.ppat.1005263. eCollection 2015.

8.

The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection.

Wu W, Liu S.

Curr Top Med Chem. 2017;17(3):361-370. Review.

PMID:
27572081
9.

VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice.

Enterlein S, Warfield KL, Swenson DL, Stein DA, Smith JL, Gamble CS, Kroeker AD, Iversen PL, Bavari S, Mühlberger E.

Antimicrob Agents Chemother. 2006 Mar;50(3):984-93.

10.

Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.

Haque A, Hober D, Blondiaux J.

Antimicrob Agents Chemother. 2015 Oct;59(10):5892-902. doi: 10.1128/AAC.01105-15. Epub 2015 Jul 27. Review.

11.

Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication.

Reynard O, Nguyen XN, Alazard-Dany N, Barateau V, Cimarelli A, Volchkov VE.

Viruses. 2015 Dec 1;7(12):6233-40. doi: 10.3390/v7122934. Erratum in: Viruses. 2016;8(5). pii: E137. doi: 10.3390/v8050137.

12.

The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus.

McMullan LK, Flint M, Dyall J, Albariño C, Olinger GG, Foster S, Sethna P, Hensley LE, Nichol ST, Lanier ER, Spiropoulou CF.

Antiviral Res. 2016 Jan;125:71-8. doi: 10.1016/j.antiviral.2015.10.010. Epub 2015 Oct 23.

PMID:
26526586
13.

Development of Potential Small Molecule Therapeutics for Treatment of Ebola Virus Disease.

Schafer A, Cheng H, Lee C, Du R, Han J, Perez J, Peet N, Manicassamy B, Rong L.

Curr Med Chem. 2018;25(38):5177-5190. doi: 10.2174/0929867324666171010141416. Review.

PMID:
29032747
15.

Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo.

Ma J, Zhang X, Soloveva V, Warren T, Guo F, Wu S, Lu H, Guo J, Su Q, Shen H, Solon E, Comunale MA, Mehta A, Guo JT, Bavari S, Du Y, Block TM, Chang J.

Antiviral Res. 2018 Feb;150:112-122. doi: 10.1016/j.antiviral.2017.12.008. Epub 2017 Dec 15.

16.

FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.

Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehár J, Hensley LE, White JM, Olinger GG.

Sci Transl Med. 2013 Jun 19;5(190):190ra79. doi: 10.1126/scitranslmed.3005471.

17.

Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry.

Henß L, Beck S, Weidner T, Biedenkopf N, Sliva K, Weber C, Becker S, Schnierle BS.

Virol J. 2016 Aug 31;13:149. doi: 10.1186/s12985-016-0607-2.

18.

Development of a broad-spectrum antiviral with activity against Ebola virus.

Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, Stavale E, Wang P, Chang S, Tang Q, Porter K, Goldblatt M, Bavari S.

Antiviral Res. 2009 Sep;83(3):245-51. doi: 10.1016/j.antiviral.2009.06.001. Epub 2009 Jun 10.

PMID:
19523489
19.

Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening.

Towner JS, Paragas J, Dover JE, Gupta M, Goldsmith CS, Huggins JW, Nichol ST.

Virology. 2005 Feb 5;332(1):20-7.

20.

Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.

Cheng H, Lear-Rooney CM, Johansen L, Varhegyi E, Chen ZW, Olinger GG, Rong L.

J Virol. 2015 Oct;89(19):9932-8. doi: 10.1128/JVI.01337-15. Epub 2015 Jul 22.

Supplemental Content

Support Center